Cardiac Biomarkers Market Performance and Future Outlook at 14.6% CAGR Through 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the cardiac biomarkers market from 2025–2034 with trusted insights from The Business Research Company

What Is The Predicted Size Of The Cardiac Biomarkers Industry By 2029?

The cardiac biomarkers market has experienced rapid expansion in recent years. It is projected to grow from $18.99 billion in 2024 to $21.19 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.6%. The market’s historical growth can be attributed to increased healthcare expenditure, FDA approvals and regulatory support, an aging population, awareness programs, the adoption of high sensitivity troponin tests, and a rise in cardiovascular diseases.

The cardiac biomarkers market size is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $36.55 billion by 2029, achieving a compound annual growth rate (CAGR) of 14.6%. This projected increase during the forecast period stems from factors such as the increasing prevalence of chronic diseases, a heightened focus on detecting diseases early, the growing elderly demographic, the advancement of developing markets, and an emphasis on biomarker panels. Key developments expected within this period encompass patient-centered healthcare approaches, the integration of AI and machine learning, digital health solutions, innovations in biomarker discovery technology, the use of multi-marker panels, and liquid biopsy techniques in cardiovascular medicine.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp

What Major Drivers Are Impacting The Cardiac Biomarkers Market?

An increasing prevalence of cardiovascular disorders is anticipated to propel the growth of the cardiac biomarker market going forward. These disorders are conditions that affect the heart and blood vessels, including coronary artery disease, heart failure, and stroke. Cardiac biomarkers are substances released into the bloodstream in response to specific cardiovascular disorders, such as myocardial infarction (heart attack), heart failure, and arrhythmias. These can be measured through laboratory tests, and their levels provide significant diagnostic and prognostic information. For instance, in September 2024, data published by the British Heart Foundation, a UK-based cardiovascular research charity, revealed that in the UK, approximately 7.6 million people are affected by heart and circulatory diseases, with about 4 million males and 3.6 million females living with these conditions. These diseases account for about 27% of all deaths in the UK, translating to over 170,000 deaths annually, or roughly 480 deaths each day, equating to one death every three minutes. Therefore, the escalating prevalence of cardiovascular disorders is driving the growth of the cardiac biomarker market.

Which Segment Categories Are Driving Maximum Growth In The Cardiac Biomarkers Market?

The cardiac biomarkersmarket covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types

2) By Location Of Testing: Point Of Care Testing, Laboratory Testing

3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications

4) By End User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-Mb): CK-Mb Test Kits, CK-Mb Diagnostic Panels

2) By Troponins: Troponin I Test Kits, Troponin T Test Kits, Troponin Diagnostic Panels

3) By Myoglobin: Myoglobin Test Kits, Myoglobin Diagnostic Panels

4) By Natriuretic Peptides (BNP And NT-proBNP): BNP Test Kits, NT-ProBNP Test Kits, Natriuretic Peptides Diagnostic Panels

5) By Ischemia Modified Albumin (IMA): IMA Test Kits, IMA Diagnostic Panels

6) By Other Biomarker Types: Heart Fatty Acid Binding Protein (HFABP), C-Reactive Protein (CRP), Other Emerging Biomarkers

Which Long-Term Trends Will Play A Crucial Role In The Cardiac Biomarkers Market?

Technological progress represents a significant and growing trend within the cardiac biomarker market. Companies operating in the cardiac biomarker market are embracing new technologies to uphold their market presence. For example, in October 2023, Mindray’s China-based medical devices company unveiled new high-sensitivity cardiac biomarkers, namely troponin I (hs-cTnI) and NT-proBNP, with the goal of improving the diagnosis and management of cardiovascular diseases (CVDs). The hs-cTnI biomarker is instrumental in detecting myocardial injury, characterized by an excellent detection rate and low imprecision, making it valuable for early screening and risk assessment in scenarios such as Acute Coronary Syndrome (ACS). In contrast, NT-proBNP is an established marker for heart failure, assisting in its detection and management, while exhibiting high precision and negligible interference from commonly used heart medications. Combined, these biomarkers considerably enhance clinical decision-making in emergency cardiovascular care.

Who Are The Dominant Players In The Cardiac Biomarkers Market Today?

Major companies operating in the cardiac biomarkers market include bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

Which Region Is At The Forefront Of Innovation In The Cardiac Biomarkers Market?

North America was the largest region in the cardiac biomarkers market in 2024. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10234&type=smp

Browse Through More Reports Similar to the Global Cardiac Biomarkers Market 2025, By The Business Research Company

Pacemakers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pacemakers-global-market-report

Cardiac Assist Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-assist-devices-and-equipment-global-market-report

Cardiac Rhythm Management Crm Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiac-rhythm-management-crm-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795